Clinical trial

GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity

Opening soon · Not applicable · 1 countries · Registry ID NCT07668765

Opening soonNot applicableObservational

What this study is about

Prospective observational cohort study evaluating the early proctologic effects of GLP-1 receptor agonist therapy in morbidly obese patients. Participants will undergo baseline and 3-month anorectal symptom assessment and proctologic examination to evaluate newly developed proctologic diseases and changes in pre-existing symptoms.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexAll

Healthy volunteersNot accepted

ConditionMorbid Obesity, Anorectal Diseases, Drug-Related Side Effects and Adverse Reactions, Constipation, Diarrhea

Full registry criteria

Inclusion Criteria: * Age ≥18 years * Morbid obesity (BMI ≥40 kg/m² or BMI ≥35 kg/m² with obesity-related comorbidities) * Newly prescribed GLP-1 receptor agonist therapy * Ability and willingness to provide written informed consent * Ability to attend 3-month follow-up visit Exclusion Criteria: * Inflammatory bowel disease * Perianal Crohn's disease * History of anorectal malignancy * Previous pelvic radiotherapy * Anorectal surgery within the previous 3 months * Pregnancy * Neurogenic bowel dysfunction * Inability to comply with follow-up visits * Discontinuation of GLP-1 receptor agonist therapy before follow-up assessment * Active anorectal infection or abscess

Treatments and study arms

GLP-1 receptor agonist therapy

Drug

Participants will receive GLP-1 receptor agonist treatment as part of routine clinical care. The study does not assign treatment but prospectively evaluates proctologic outcomes following treatment initiation.

Primary outcomes

Incidence of newly developed proctologic disease3 months

Patients developing newly diagnosed anorectal pathology after initiation of GLP-1 receptor agonist therapy, including hemorrhoidal disease, anal fissure, pruritus ani, perianal irritation, or other proctologic conditions identified during follow-up examination.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Gazi University Faculty of Medicine🌐 Ankara, Turkey (Türkiye)

Open map

mESUT Yavaş, MDContact

Email · Call +903122025719